您好,欢迎来到试剂信息网! [登录] [免费注册]
试剂信息网
位置:首页 > 产品库 > Cabozantinib malate(XL184)
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Cabozantinib malate(XL184)
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Cabozantinib malate(XL184)图片
CAS NO:1140909-48-3
规格:≥98%
包装与价格:
包装价格(元)
100mg电议
250mg电议
500mg电议
1g电议
2g电议
5g电议

产品介绍
理化性质和储存条件
Molecular Weight (MW)635.59
FormulaC28H24FN3O5.C4H6O5
CAS No.1140909-48-3(malate);
Storage-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)DMSO: 100 mg/mL (157.3 mM)
Water:<1 mg/mL
Ethanol:<1 mg/mL
Solubility (In vivo)30% propylene glycol, 5% Tween 80, 65% D5W: 15mg/mL
SynonymsCabozantinib malate; XL-184; BMS-907351; XL184; XL 184; BMS907351; BMS 907351; Cabozantinib S-malate. Brand name: Cometriq.

Chemical Name: N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)phenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide (S)-2-hydroxysuccinate

InChi Key: HFCFMRYTXDINDK-WNQIDUERSA-N

InChi Code: InChI=1S/C28H24FN3O5.C4H6O5/c1-35-24-15-21-22(16-25(24)36-2)30-14-11-23(21)37-20-9-7-19(8-10-20)32-27(34)28(12-13-28)26(33)31-18-5-3-17(29)4-6-18;5-2(4(8)9)1-3(6)7/h3-11,14-16H,12-13H2,1-2H3,(H,31,33)(H,32,34);2,5H,1H2,(H,6,7)(H,8,9)/t;2-/m.0/s1

SMILES Code: COC1=CC2=C(OC3=CC=C(NC(C4(C(NC5=CC=C(F)C=C5)=O)CC4)=O)C=C3)C=CN=C2C=C1OC.O=C(O)[C@@H](O)CC(O)=O

实验参考方法
In Vitro

In vitro activity: XL184 has weak inhibitory activity against RON and PDGFRβ with IC50 of 124 nM and 234 nM, respectivey, and has low activity against FGFR1 with IC50 of 5.294 μM. XL184 at low concentration (0.1-0.5 μM) is sufficient to induce marked inhibition of constitutive and inducible Met phosphorylation and its resultant downstream signaling in MPNST cells, and inhibit HGF-induced MPNST cell migration and invasion. XL184 also induces marked inhibition of Met and VEGFR2 phosphorylation in cytokine-stimulated human umbilical vein endothelial cells (HUVECs). Although XL-184 has no significant effect on MPNST cell growth at 0.1 μM, XL184 at 5-10 μM significantly inhibits the MPNST cell growth.


Kinase Assay: Cabozantinib (XL184, BMS-907351) is a potent VEGFR2 inhibitor with IC50 of 0.035 nM and also inhibits c-Met, Ret, Kit, Flt-1/3/4, Tie2, and AXL with IC50 of 1.3 nM, 4 nM, 4.6 nM, 12 nM/11.3 nM/6 nM, 14.3 nM and 7 nM, respectively.


Cell Assay: Cells (ST88-14, STS26T, and MPNST724) are exposed to various concentrations of XL184 for 48 hours. Cell growth is determined by MTS assays using CellTiter96 Aqueous Non-Radioactive Cell Proliferation Assay kit. Absorbance is measured at a wavelength of 490 nm, and the absorbance values of treated cells are presented as a percentage of the absorbance of untreated cells.

In VivoXL184 treatment at 30 mg/kg in RIP-Tag2 mice with spontaneous pancreatic islet tumors disrupts 83% of the tumor vasculature, reduces pericytes and empty basement membrane sleeves, causes widespread intratumoral hypoxia and extensive tumor cell apoptosis, and slows regrowth of the tumor vasculature after drug withdrawal, more significantly compared with XL999 that blocks VEGFR but not c-Met, leading to only 43% reduction in vascularity, suggesting that concurrent inhibition of VEGFR and other functionally relevant receptor tyrosine kinases (RTK) amplifies angiogenesis inhibition. XL184 also decreases invasiveness of primary tumors and reduces metastasis. XL184 at 30 mg/kg/day significantly abrogates human MPNST xenografts growth and metastasis in SCID mice. Administration of XL184 induces dose-dependent inhibition of tumor growth in breast, lung, and glioma tumor models, in association with decreased tumor and endothelial cell proliferation as well as increased apoptosis. A single oral dose of XL184 is sufficient to induce sustained tumor growth inhibition in MDA-MB-231 tumor-bearing mice and C6 tumor-bearing rats at 100 mg/kg and 10 mg/kg, respectively.
Animal modelRIP-Tag2 transgenic mice in a C57BL/6 background with spontaneous pancreatic islet tumors
Formulation & DosageSuspended at a concentration of 5 mg/mL in sterile saline; 60mg/kg; Oral gavage
ReferencesCancer Res. 2011 Jul 15;71(14):4758-68; Clin Cancer Res. 2011 Jun 15;17(12):3943-55; Mol Cancer Ther. 2011 Dec;10(12):2298-308.
生物活性


The multi-tyrosine kinase inhibitor, XL184, targeting MET and VEGFR2 abrogates MPNST migration, invasion, and angiogenesis. Clin Cancer Res. 2011 Jun 15;17(12):3943-55.



XL184 abrogates local and metastatic MPNST growth in vivo. Clin Cancer Res. 2011 Jun 15;17(12):3943-55.